Mirati Shares Fall On New Data For Lung Cancer Drug Combo | Enterpreneurship

Want create site? Free WordPress Themes and plugins.

Shares of San Diego-based Mirati Therapeutics fell 15 percent Monday as data from an ongoing mid-stage study of one of its experimental cancer drugs disappointed investors.

Mirati (NASDAQ: MRTX) is one of several biotech companies trying to get in on the mix-and-match cancer immunotherapy game. Drugmakers have been combining immunotherapies with other medicines hoping to help more patients respond, and that has led to a slew of deals and alliances to test various regimens in clinical trials. Results so far have been mixed.

Mirati, for , has been testing sitravatinib (MGCD516) in combination with nivolumab (Opdivo), an immunotherapy from… Read more »

UNDERWRITERS AND PARTNERS

Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.